London, July 18, 2025 — In a groundbreaking medical achievement, scientists from Newcastle University in the United Kingdom have reported the successful birth of eight healthy children using a three-person in vitro fertilization (IVF) technique designed to prevent the inheritance of devastating mitochondrial diseases. The findings mark a significant milestone in reproductive medicine and offer hope to families at risk of passing on these incurable genetic disorders.
The technique, known as mitochondrial donation or pronuclear transfer, involves transferring the nuclear DNA from a mother’s fertilized egg, which carries disease-causing mitochondrial mutations, into a healthy donor egg with its nuclear DNA removed. The resulting embryo contains the genetic material of the biological parents and healthy mitochondria from the donor, earning the procedure the nickname “three-person IVF.” Mitochondria, the cell’s energy-producing structures, contain their own DNA, and mutations in this DNA can lead to severe, often fatal disorders affecting energy-intensive organs like the brain, heart, muscles, and liver.
The trial, conducted at the Newcastle Fertility Centre, involved 22 women at high risk of transmitting mitochondrial DNA mutations to their children. Of these, seven women gave birth to eight healthy babies—four boys and four girls, including a set of identical twins—and one woman is currently pregnant. Blood tests revealed that six of the newborns had no detectable mitochondrial mutations, while two had significantly reduced levels (77% to 88% lower than their mothers), deemed unlikely to cause disease. All children are meeting developmental milestones, with five under one year old, two between one and two years, and one older.
“This is a landmark study on preventing mitochondrial disease,” said Dietrich Egli, a stem-cell scientist at Columbia University, who was not involved in the research. “The results are a triumph of scientific innovation, offering families a chance at healthy children.”
The UK became the first country to legalize mitochondrial donation in 2015, following extensive research, ethical debates, and public consultation. The Newcastle Fertility Centre, the only clinic licensed by the UK’s Human Fertilisation and Embryology Authority (HFEA) to perform the procedure, began its trial in 2017. The technique is banned in the United States due to restrictions on heritable genetic modifications, though it is permitted in Australia under strict regulations.
Despite the success, researchers remain cautious. In three children, low levels of mutant mitochondria (5% to 16%) were detected, raising concerns about “reversal,” where mutated mitochondria could multiply over time. While these levels are unlikely to cause disease, long-term monitoring is recommended, particularly for the two female children who could potentially pass mutations to their offspring. Prenatal genetic testing could mitigate this risk, experts say.
“We’re cautiously optimistic about these results,” said Robert McFarland, a pediatric neurologist at Newcastle University and co-leader of the study. “To see babies born free of mitochondrial disease is remarkable.”
The procedure is not without controversy. Critics, including some in the US and Canada, argue that long-term health impacts on children born through mitochondrial donation remain unknown, urging further research before widespread adoption. Others highlight ethical concerns about manipulating human embryos. However, proponents argue the technique targets only mitochondrial DNA—less than 0.2% of the genome—and does not affect traits like appearance or personality.
For families, the results are deeply personal. One mother, who remained anonymous, shared, “After years of uncertainty, this treatment gave us hope—and then our baby. We’re overwhelmed with gratitude.” Another parent echoed, “Science gave us a chance at a healthy child.”
The Newcastle team’s work, described as a “tour de force” by reproductive medicine specialist Andy Greenfield of the University of Oxford, is expected to inspire further research. In Australia, where mitochondrial donation is legal under Maeve’s Law, scientists hope to launch similar trials soon. The technique could benefit thousands worldwide, with estimates suggesting it could prevent mitochondrial diseases in approximately 150 UK babies and 770 US babies annually if adopted.
As the global scientific community watches closely, the Newcastle trial underscores the potential of mitochondrial donation to transform lives, while highlighting the need for ongoing vigilance to ensure the safety and efficacy of this pioneering approach.
